Previous Close | 35.53 |
1-Year Change | -24.4% |
6-Months Change | -37.58% |
3-Months Change | -10.57% |
Moving Avg (50d) | 38.062 |
Moving Avg (200d) | 50.373 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.27M |
Beta (3-Years) | 0.97 |
Revenue Growth (ttm) | 141.38% |
Net Profit Margin (ttm) | -222.09% |
Return On Assets (ttm) | -74.07% |
EPS (ttm) | -3751.32 |
PE Ratio (ttm) | -0.01 |
Dividend Yield | % |
Asset Description: | Apellis Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
36.241 | 37.306 | 38.017 | 39.083 | 40.859 | 42.636 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.